{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T18:22:00Z","timestamp":1794075720867,"version":"4.8.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100032148","name":"Biohaven Pharmaceuticals, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032148","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40120-026-00891-6","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T12:55:30Z","timestamp":1771419330000},"page":"807-816","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Incorporating Patient Perspectives into a Composite Score for Measuring Disease Progression in Spinocerebellar Ataxia (SCA)"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7389-3354","authenticated-orcid":false,"given":"Michele H.","family":"Potashman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basia M.","family":"Rogula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren C.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen E.","family":"Korol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam P.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hendrix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Rudell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Abetz-Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa W.","family":"Beiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Coric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana S.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Perlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy D.","family":"Schmahmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"L\u2019Italien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"issue":"2","key":"891_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/14737175.2022.2029703","volume":"22","author":"SD Ghanekar","year":"2022","unstructured":"Ghanekar SD, Kuo SH, Staffetti JS, Zesiewicz TA. Current and emerging treatment modalities for spinocerebellar ataxias. Expert Rev Neurother. 2022;22(2):101\u201314.","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"891_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41572-019-0074-3","volume":"5","author":"T Klockgether","year":"2019","unstructured":"Klockgether T, Mariotti C, Paulson HL. Spinocerebellar ataxia. Nat Rev Dis Primers. 2019;5(1):24.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"891_CR3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s12311-010-0183-8","volume":"9","author":"I Klinke","year":"2010","unstructured":"Klinke I, Minnerop M, Schmitz-H\u00fcbsch T, et al. Neuropsychological features of patients with spinocerebellar ataxia (SCA) types 1, 2, 3, and 6. Cerebellum. 2010;9(3):433\u201342.","journal-title":"Cerebellum"},{"issue":"2","key":"891_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00415-018-9076-4","volume":"266","author":"R Sullivan","year":"2019","unstructured":"Sullivan R, Yau WY, O\u2019Connor E, Houlden H. Spinocerebellar ataxia: an update. J Neurol. 2019;266(2):533\u201344.","journal-title":"J Neurol"},{"issue":"8","key":"891_CR5","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1007\/s00415-020-09815-2","volume":"268","author":"A Diallo","year":"2021","unstructured":"Diallo A, Jacobi H, du Tezenas Montcel S, Klockgether T. Natural history of most common spinocerebellar ataxia: a systematic review and meta-analysis. J Neurol. 2021;268(8):2749\u201356.","journal-title":"J Neurol"},{"issue":"10","key":"891_CR6","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1002\/acn3.51875","volume":"10","author":"H Jacobi","year":"2023","unstructured":"Jacobi H, Schaprian T, Schmitz-H\u00fcbsch T, et al. Disease progression of spinocerebellar ataxia types 1, 2, 3 and 6 before and after ataxia onset. Ann Clin Transl Neurol. 2023;10(10):1833\u201343.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"891_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/mds.29255","volume":"38","author":"P Moulaire","year":"2023","unstructured":"Moulaire P, Poulet PE, Petit E, et al. Temporal dynamics of the scale for the assessment and rating of ataxia in spinocerebellar ataxias. Move Disord. 2023;38(1):35\u201344.","journal-title":"Move Disord"},{"key":"891_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-024-01707-9","author":"M Potashman","year":"2024","unstructured":"Potashman M, Popoff E, Powell L, et al. Psychometric validation of the modified functional scale for the assessment and rating of ataxia (f-SARA) in patients with spinocerebellar ataxia. Cerebellum. 2024. https:\/\/doi.org\/10.1007\/s12311-024-01707-9.","journal-title":"Cerebellum"},{"key":"891_CR9","unstructured":"US Department of Health and Human Services, Food & Drug Administration, Center for Devices and Radiological Health, Center for Biologics Evaluation and Research. Principles for Selecting, Developing, Modifying, and Adapting Patient Reported Outcome Instruments for Use in Medical Device Evaluation: Guidance for Industry and Food and Drug Administration Staff, And Other Stakeholders. January 26, 2022. https:\/\/www.federalregister.gov\/documents\/2022\/01\/26\/2022-01377\/principles-for-selecting-developing-modifying-and-adapting-patient-reported-outcome-instruments-for"},{"key":"891_CR10","unstructured":"Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Patient-focused drug development: collecting comprehensive and representative input: guidance for industry, food and drug administration staff, and other stakeholders. 2020; https:\/\/www.fda.gov\/media\/139088\/download. Accessed 2 Oct 2023."},{"key":"891_CR11","unstructured":"Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Patient-focused drug development: methods to identify what is important to patients: guidance for industry, food and drug administration staff, and other stakeholders. 2020; https:\/\/www.fda.gov\/media\/131230\/download. Accessed 2 Oct 2023."},{"key":"891_CR12","unstructured":"International Council for Harmonisation (ICH). ICH Reflection Paper: Proposed ICH Guideline Work to Advance Patient Focused Drug Development. 2021; https:\/\/admin.ich.org\/sites\/default\/files\/2021-06\/ICH_ReflectionPaper_PFDD_FinalRevisedPostConsultation_2021_0602.pdf. Accessed 12 Sep 12 2025."},{"issue":"5","key":"891_CR13","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s12311-025-01896-x","volume":"24","author":"M Potashman","year":"2025","unstructured":"Potashman M, Heinrich M, Rudell K, et al. Content validity of the spinocerebellar ataxia composite score as a measure of disease progression in patients with spinocerebellar ataxia. Cerebellum. 2025;24(5):146.","journal-title":"Cerebellum"},{"issue":"5","key":"891_CR14","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1007\/s12311-024-01697-8","volume":"23","author":"G L'Italien","year":"2024","unstructured":"L\u2019Italien G, Popoff E, Rogula B, et al. Development and validation of SCACOMS, a composite scale for assessing disease progression and treatment effects in spinocerebellar ataxia. Cerebellum. 2024;23(5):2028\u201341.","journal-title":"Cerebellum"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00891-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00891-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00891-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:08:05Z","timestamp":1772798885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00891-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["891"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00891-6","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gil L\u2019Italien, Michele Potashman, Melissa Beiner and Vlad Coric are employees of Biohaven Pharmaceuticals, Inc. Basia Rogula, Lauren Powell, and Ellen Korol, employees of Broadstreet HEOR which was contracted by Biohaven Pharmaceuticals, Inc for the conduct of this study. Samuel P. Dickson and Suzanne Hendrix are employees of Pentara Corporation which was contracted by Biohaven Pharmaceuticals, Inc for the conduct of this study. Maggie Heinrich is an employee of Parexel which was contracted by Biohaven Pharmaceuticals, Inc for the conduct of this study. Katja Rudell was an employee of Paraxel at the point of data collection. Linda Abetz-Webb provided clinical outcomes assessments consulting to Parexel on this study and provides clinical outcomes assessments consulting across the pharmaceutical industry across rare disease areas. Liana S. Rosenthal received consulting fees from Biohaven Pharmaceuticals, Inc. Dr. Rosenthal is an Associate Professor in the Department of Neurology at the Johns Hopkins University School of Medicine. Dr. Rosenthal engaged in this research as a private consultant or advisor and not in her capacity as a Johns Hopkins faculty member. Dr. Rosenthal was compensated for the consulting or advising service in income. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Susan Perlman has nothing to disclose. Jeremy Schmahmann receives consulting fees from Biohaven Pharmaceuticals, Inc., is site Principal Investigator for Biohaven Pharmaceuticals, Inc. in clinical trials in ataxia and multiple system atrophy, and for IntraBio in clinical trials in ataxia telangiectasia. Research support, commercial entities: Biohaven Pharmaceuticals, Inc. unrestricted grant for the study of multiple system atrophy imaging biomarkers. Research support, foundations, and societies: National Ataxia, Great Oaks, Once Upon A Time, ARSACS and MINDlink Foundations. Principal Investigator license fee payments. Technology or inventions: Inventor, Brief Ataxia Rating Scale (BARS), Brief Ataxia Rating Scale revised (BARS2), Cerebellar Cognitive Affective\/Schmahmann syndrome Scale, Patient-Reported Outcome Measure of Ataxia, Cerebellar Neuropsychiatric Rating Scale, Cerebellar Neuropsychiatric Rating Scale version 2, to which copyright is held by The Massachusetts General Hospital Corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethics approval was not required for this study as it did not involve the recruitment of subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}